LAMEA Oncology/Anti-Cancer Drugs Market Manufacturers, Regions, Types, Major Drivers, Revenue

LAMEA Oncology/Anti-Cancer Drugs Market report, published by Allied Market Research, forecasts that the market is expected to garner $17,072.2 million by 2021, registering a CAGR of 8.6% during the period 2015 - 2021. Chemotherapy segment is expected to maintain a dominant share in the LAMEA oncology/cancer drugs market during the forecast period.

Key findings of LAMEA Oncology/Anti-Cancer Drugs Market:

• Immunotherapy (biologic therapy) is projected to be the fastest growing segment, registering a CAGR of 12.2% during the forecast period.

• Chemotherapy is expected to dominate the LAMEA oncology/cancer drugs market throughout the forecast period.

• Blood cancer segment would lead the LAMEA oncology/cancer drugs market through 2021.

• Algeria is anticipated to be the fastest growing country in the LAMEA oncology/anti-cancer drugs market, registering a CAGR of 12.8% between 2015 and 2021.

• Brazil was the highest revenue generating country in the LAMEA oncology/anti-cancer drugs market with about one third of market share in 2015.

Get sample copy of this report at:
www.alliedmarketresearch.com/request-sample/863

High prevalence and rising incidence rates of major types of cancers (such as breast cancer and prostate cancer), emerging treatment algorithms and widespread use of anti-cancer drugs for treating conditions such as blood cancer (leukemia) is expected to drive this market. In addition, growing popularity of biological and targeted drug therapies, which help in improving the patientssurvival time, are projected to provide opportunities in the LAMEA oncology/anti-cancer drugs market. However, factors such as high cost associated with cancer drugs and related side effects are likely to affect the market growth.

Saudi Arabia, is the leading country market from the Middle East region and would continue to lead until 2020, owing to rising incidence rates of cancer, high healthcare expenditure and gross national income (GNI) in Saudi Arabia. Algeria, is expected to witness highest growth rate because of considerable funding, urbanized healthcare facilities and establishment of national healthcare systems. Furthermore, acquisition is the key growth strategy adopted by the leading players in the market, which helped companies to expand their oncology drugs business.

Send Enquiry on this report @
https://www.alliedmarketresearch.com/purchase-enquiry/863

Key players:

• Amgen Inc.
• AstraZeneca Plc.
• Roche Diagnostics
• GlaxoSmithKline PLC
• Merck & Co.
• Novartis AG
• AbbVie Inc. Sanofi
• EIMC United Pharmaceuticals (EUP)
• Actavis plc.

Table of content:

Chapter: 1 INTRODUCTION

1.1 Report description
1.2 Key benefits
1.3 Key market segment
1.4 Research methodology

1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

Chapter: 3 MARKET OVERVIEW

3.1 Market definition and scope
3.2 Development of novel immuno-oncology drug products
3.3 Key findings

3.3.1 Top impacting factors
3.3.2 Top investment pockets
3.3.3 Top winning strategies

3.4 Government regulations

3.4.1 Regulations in Middle East

3.5 Reimbursement scenario

3.5.1 Reimbursement in Middle East

3.6 Drivers

3.6.1 Rising incidence and prevalence of various cancer types
3.6.2 Growing importance of biological and targeted drug therapies
3.6.3 Increasing funding and aid from public and private sector

3.7 Restraints

3.7.1 High cost of drug development and threat of failure
3.7.2 Adverse effects of cancer drug therapy

3.8 Opportunities

3.8.1 Advancement of anti-cancer drugs research
3.8.2 Healthcare and medical awareness

List of Figures

FIG. 1 TOP FACTORS IMPACTING ANTI-CANCER DRUGS MARKET (2014-2021)
FIG. 2 TOP INVESTMENT POCKETS OF ONCOLOGY/ANTI-CANCER DRUGS MARKET (2014)
FIG. 3 TOP WINNING STRATEGIES FOR GLOBAL CANCER DRUG MARKET (2011-2015)
FIG. 4 TOP WINNING STRATEGIES BY SUBTYPE (2011-2015)
FIG. 5 PERCENTAGE (%) OF ALL NEW CANCERS CASES DIAGNOSED IN 2012
FIG. 6 LAMEA CHEMOTHERAPY DRUGS MARKET, 2014-2021 ($MILLION)
FIG. 7 LAMEA TARGETED THERAPY DRUGS MARKET, 2014-2021 ($MILLION)
FIG. 8 LAMEA IMMUNOTHERAPY DRUGS MARKET, 2014-2021 ($MILLION)
FIG. 9 LAMEA HORMONAL THERAPY DRUGS MARKET, 2014-2021 ($MILLION)
FIG. 10 LAMEA OTHER DRUGS MARKET, 2014-2021 ($MILLION)
FIG. 11 LAMEA BLOOD CANCER DEATH RATE (PER 100,000), (2014)
FIG. 12 LAMEA BLOOD CANCER MARKET, 2014-2021 ($MILLION)
FIG. 13 LAMEA BREAST CANCER DEATH RATE (PER 100,000), 2014
FIG. 14 LAMEA BREAST CANCER MARKET, 2014-2021 ($MILLION)
FIG. 15 LAMEA GASTROINTESTINAL CANCER DEATH RATE (PER 100,000), 2014
FIG. 16 LAMEA GASTROINTESTINAL CANCER MARKET, 2014-2021 ($MILLION)
FIG. 17 LAMEA PROSTATE CANCER DEATH RATE (PER 100,000), 2014
FIG. 18 LAMEA PROSTATE CANCER MARKET, 2014-2021 ($MILLION)
FIG. 19 LAMEA RESPIRATORY/LUNG CANCER DEATH RATE (PER 100,000), 2014
FIG. 20 LAMEA RESPIRATORY/LUNG CANCER MARKET, 2014-2021 ($MILLION)
FIG. 21 LAMEA SKIN CANCER DEATH RATE (PER 100,000), 2014
FIG. 22 LAMEA SKIN CANCER MARKET, 2014-2021 ($MILLION)
FIG. 23 LAMEA OTHER CANCER MARKET, 2014-2021 ($MILLION)
FIG. 24 AMGEN INC. REVENUE BY GEOGRAPHY (2014)
FIG. 25 AMGEN INC. REVENUE BY PRODUCT PORTFOLIO (2014)
FIG. 26 SWOT ANALYSIS OF AMGEN INC.
FIG. 27 FINANCIAL REVENUES BY GEOGRAPHY (2014)
FIG. 28 FINANCIAL REVENUES BY YEAR, 2014 ($MILLION)
FIG. 29 SWOT ANALYSIS AND STRATEGIC CONCLUSIONS
FIG. 30 ROCHE DIAGNOSTICS BY BUSINESS UNITS (2014)

Access full summary of this report at:
www.alliedmarketresearch.com/lamea-oncology-anti-cancer-d...

About Us:

Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
Deep Joshi
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1?855?550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

This release was published on openPR.